Skip to main content
Top
Published in: International Urology and Nephrology 8/2019

01-08-2019 | Prostate Cancer | Urology - Original Paper

Assessment of men’s risk thresholds to proceed with prostate biopsy for the early detection of prostate cancer

Authors: Kevin Koo, Elias S. Hyams

Published in: International Urology and Nephrology | Issue 8/2019

Login to get access

Abstract

Purpose

To delineate the range of “risk thresholds” for prostate biopsy to determine how improved prostate cancer (CaP) risk prediction tools may impact shared decision-making (SDM).

Methods

We conducted a cross-sectional survey study involving men 45–75 years old attending a multispecialty urology clinic. Data included demographics, personal and family prostate cancer history, and prostate biopsy history. Respondents were presented with a summary of the details, risks, and benefits of prostate biopsy, then asked to indicate the specific risk threshold (% chance) of high-grade CaP at which they would proceed with prostate biopsy.

Results

Of a total of 103 respondents, 18 men (17%) had a personal history of CaP, and 31 (30%) had undergone prostate biopsy. The median risk threshold to proceed with prostate biopsy was 25% (interquartile range 10–50%). Risk thresholds did not vary by race, education, or employment. Personal history of CaP or prostate biopsy was significantly associated with lower mean risk thresholds (19% vs. 32% [P = 0.02] and 23% vs. 33% [P = 0.04], respectively). In the lowest versus highest risk threshold quartiles, there were significantly higher rates of CaP (36% vs. 1%, P = 0.01) and prior prostate biopsy (46% vs. 17%, P < 0.01).

Conclusions

Men have a wide range of risk thresholds for high-grade CaP to proceed with prostate biopsy. Men with a prior history of CaP or biopsy reported lower risk thresholds, which may reflect their greater concern for this disease. The extent to which refined risk prediction tools will improve SDM warrants further study.
Appendix
Available only for authorised users
Literature
3.
9.
go back to reference Chiu PK, Roobol MJ, Teoh JY, Lee WM, Yip SY, Hou SM et al (2016) Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume. Int Urol Nephrol 48(10):1631–1637. https://doi.org/10.1007/s11255-016-1350-8 CrossRefPubMed Chiu PK, Roobol MJ, Teoh JY, Lee WM, Yip SY, Hou SM et al (2016) Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume. Int Urol Nephrol 48(10):1631–1637. https://​doi.​org/​10.​1007/​s11255-016-1350-8 CrossRefPubMed
21.
go back to reference Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G et al (2016) European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. BJU Int 118(5):706–713. https://doi.org/10.1111/bju.13437 CrossRefPubMed Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G et al (2016) European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. BJU Int 118(5):706–713. https://​doi.​org/​10.​1111/​bju.​13437 CrossRefPubMed
23.
go back to reference Dijkstra S, Govers TM, Hendriks RJ, Schalken JA, Van Criekinge W, Van Neste L et al (2017) Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics—a decision analytical model. BJU Int 120(5):659–665. https://doi.org/10.1111/bju.13861 CrossRefPubMed Dijkstra S, Govers TM, Hendriks RJ, Schalken JA, Van Criekinge W, Van Neste L et al (2017) Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics—a decision analytical model. BJU Int 120(5):659–665. https://​doi.​org/​10.​1111/​bju.​13861 CrossRefPubMed
24.
go back to reference Voigt JD, Dong Y, Linder V, Zappala S (2017) Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: overall cost savings and improved quality of care to the us healthcare system. Rev Urol 19(1):1–10PubMedPubMedCentral Voigt JD, Dong Y, Linder V, Zappala S (2017) Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: overall cost savings and improved quality of care to the us healthcare system. Rev Urol 19(1):1–10PubMedPubMedCentral
26.
go back to reference Gokce MI, Wang X, Frost J, Roberson P, Volk RJ, Brooks D et al (2017) Informed decision making before prostate-specific antigen screening: initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men. Cancer 123(4):583–591. https://doi.org/10.1002/cncr.30367 CrossRefPubMed Gokce MI, Wang X, Frost J, Roberson P, Volk RJ, Brooks D et al (2017) Informed decision making before prostate-specific antigen screening: initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men. Cancer 123(4):583–591. https://​doi.​org/​10.​1002/​cncr.​30367 CrossRefPubMed
27.
go back to reference Arterburn D, Wellman R, Westbrook EO, Ross TR, McCulloch D, Handley M et al (2015) Decision aids for benign prostatic hyperplasia and prostate cancer. Am J Manag Care 21(2):e130–e140PubMed Arterburn D, Wellman R, Westbrook EO, Ross TR, McCulloch D, Handley M et al (2015) Decision aids for benign prostatic hyperplasia and prostate cancer. Am J Manag Care 21(2):e130–e140PubMed
Metadata
Title
Assessment of men’s risk thresholds to proceed with prostate biopsy for the early detection of prostate cancer
Authors
Kevin Koo
Elias S. Hyams
Publication date
01-08-2019
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 8/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-019-02196-0

Other articles of this Issue 8/2019

International Urology and Nephrology 8/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.